Abstract
Cyclic guanosine 3',5'-monophosphate (cGMP) mediates a wide spectrum of physiologic processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at any step of the cascade - cGMP synthesis, effector activation, or catabolism - have been implicated in numerous cardiovascular diseases, ranging from hypertension to atherosclerosis to cardiac hypertrophy and heart failure. In this review, we outline each step of the cGMP signaling cascade and discuss its regulation and physiologic effects within the cardiovascular system. In addition, we illustrate how cGMP signaling becomes dysregulated in specific cardiovascular disease states. The ubiquitous role cGMP plays in cardiac physiology and pathophysiology presents great opportunities for pharmacologic modulation of the cGMP signal in the treatment of cardiovascular diseases. We detail the various therapeutic interventional strategies that have been developed or are in development, summarizing relevant preclinical and clinical studies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 216-238 |
| Number of pages | 23 |
| Journal | Pharmacology and Therapeutics |
| Volume | 122 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 2009 |
Fingerprint
Keywords
- Cardiovascular disease
- cGMP
- Natriuretic peptide receptor
- Phosphodiesterases
- PKG
- Soluble guanylyl cyclase
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. / Tsai, Emily J.; Kass, David A.
In: Pharmacology and Therapeutics, Vol. 122, No. 3, 06.2009, p. 216-238.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics
AU - Tsai, Emily J.
AU - Kass, David A
PY - 2009/6
Y1 - 2009/6
N2 - Cyclic guanosine 3',5'-monophosphate (cGMP) mediates a wide spectrum of physiologic processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at any step of the cascade - cGMP synthesis, effector activation, or catabolism - have been implicated in numerous cardiovascular diseases, ranging from hypertension to atherosclerosis to cardiac hypertrophy and heart failure. In this review, we outline each step of the cGMP signaling cascade and discuss its regulation and physiologic effects within the cardiovascular system. In addition, we illustrate how cGMP signaling becomes dysregulated in specific cardiovascular disease states. The ubiquitous role cGMP plays in cardiac physiology and pathophysiology presents great opportunities for pharmacologic modulation of the cGMP signal in the treatment of cardiovascular diseases. We detail the various therapeutic interventional strategies that have been developed or are in development, summarizing relevant preclinical and clinical studies.
AB - Cyclic guanosine 3',5'-monophosphate (cGMP) mediates a wide spectrum of physiologic processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at any step of the cascade - cGMP synthesis, effector activation, or catabolism - have been implicated in numerous cardiovascular diseases, ranging from hypertension to atherosclerosis to cardiac hypertrophy and heart failure. In this review, we outline each step of the cGMP signaling cascade and discuss its regulation and physiologic effects within the cardiovascular system. In addition, we illustrate how cGMP signaling becomes dysregulated in specific cardiovascular disease states. The ubiquitous role cGMP plays in cardiac physiology and pathophysiology presents great opportunities for pharmacologic modulation of the cGMP signal in the treatment of cardiovascular diseases. We detail the various therapeutic interventional strategies that have been developed or are in development, summarizing relevant preclinical and clinical studies.
KW - Cardiovascular disease
KW - cGMP
KW - Natriuretic peptide receptor
KW - Phosphodiesterases
KW - PKG
KW - Soluble guanylyl cyclase
UR - http://www.scopus.com/inward/record.url?scp=67349149420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349149420&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2009.02.009
DO - 10.1016/j.pharmthera.2009.02.009
M3 - Article
C2 - 19306895
AN - SCOPUS:67349149420
VL - 122
SP - 216
EP - 238
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
SN - 0163-7258
IS - 3
ER -